Oxytocin and Social Cognition in Frontotemporal Dementia
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01002300
Recruitment Status :
First Posted : October 27, 2009
Last Update Posted : March 18, 2014
Lawson Health Research Institute
The Alzheimer Society London and Middlesex
Information provided by (Responsible Party):
Elizabeth Finger, Lawson Health Research Institute
Investigations into the components of cognition damaged in frontotemporal dementia (FTD) demonstrate that patients with FTD show deficits in facial and verbal expression recognition, lack insight into what others think or might do (theory of mind skills), and in decision making tasks requiring processing of positive versus negative feedback. These cognitive functions are thought to be critical for appropriate social behavioural regulation (Blair, 2003). Recent studies in animal models and humans suggest that the neuropeptide oxytocin is an important mediator of social behavior and that oxytocin may facilitate emotion recognition, theory of mind processing, and prosocial behaviors (Donaldson and Young, 2008). Together, these findings suggest that upregulation of oxytocin dependent mechanisms of social and emotional cognition may be a valuable treatment approach in patients with FTD. The aim of this study is to determine how administration of intranasal oxytocin to patients with frontotemporal dementia affects behavior and processing of specific types of social and emotional information.The investigators' hypothesis is that oxytocin administration will improve emotional and social cognitive deficits in patients with FTD, resulting in improved decision making and behaviour.
Participants will receive 24 IU of oxytocin or placebo (Salinex saline nasal spray) intranasally 30 minutes prior to completing the experimental tasks. Two weeks later participants will return for a second visit and receive the alternate drug (either intranasal oxytocin or Salinex) prior to completing the experimental tasks.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
30 Years to 80 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Clinical diagnosis of probable Frontotemporal Dementia or Pick's disease
Caregiver available to participate in all study visits
Severe language or memory deficits that preclude completion of the cognitive tasks
Females who are pregnant or breastfeeding (a pregnancy test will be done on females who have not completed menopause)
Bradycardia (rate <50 bpm) or tachycardia (rate > 100 bpm)
Current use of prostaglandins
Use of any investigational or experimental drug or device within the last 60 days prior to screening or within 5 half-lives of the experimental drug , whichever is longer
Keywords provided by Elizabeth Finger, Lawson Health Research Institute:
Additional relevant MeSH terms:
Aphasia, Primary Progressive
Pick Disease of the Brain
Central Nervous System Diseases
Nervous System Diseases
Frontotemporal Lobar Degeneration
Signs and Symptoms
Reproductive Control Agents
Physiological Effects of Drugs